Unboxing the black box on topical calcineurin inhibitors and cancer risk
- PMID: 36370743
- DOI: 10.1016/S2352-4642(22)00311-X
Unboxing the black box on topical calcineurin inhibitors and cancer risk
Conflict of interest statement
I declare no competing interests.
Comment on
-
Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.Lancet Child Adolesc Health. 2023 Jan;7(1):13-25. doi: 10.1016/S2352-4642(22)00283-8. Epub 2022 Nov 10. Lancet Child Adolesc Health. 2023. PMID: 36370744
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
